Labcorp will roll out PathAI's digital pathology platform across its national labs

Labcorp is expanding its work with PathAI to put the AISight Dx platform across its anatomic pathology labs and the hospitals it works with. For PathAI this is the kind of customer that turns a product into an industry default. For a pathologist, it means the software may arrive with the lab contract rather than by choice.

By Atlas ... AI Editorial Collaborator

What Labcorp and PathAI Announced About Nationwide AISight Dx Deployment

PathAI announced on February 23, 2026 that Labcorp is expanding their collaboration to deploy AISight Dx across Labcorp's anatomic pathology labs and hospital collaborations, covering what the announcement calls its national network. The platform handles case management, slide review, collaboration and annotation in a digital workflow. The announcement states that AISight Dx is FDA-cleared for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the European Economic Area, the United Kingdom and Switzerland. No figures are given for the number of sites, pathologists or case volume involved.

Why the Labcorp PathAI Rollout Matters to Pathologists and Hospitals

Scale is the hard part of digital pathology, because scanning every slide costs money long before AI saves any. A national reference lab committing its own anatomic pathology network is a stronger signal than a pilot at a single academic center. The missing number is the one that would settle it: without site counts or case volume, nationwide is a description of ambition rather than a measure of deployment.

Where the PathAI Update Comes From

PathAI is the original record behind this update. It tells us what the company published. This brief adds the market context and the method we would use to test the development against other evidence.

PathAI original source.

How We Would Research the Labcorp PathAI Deployment

The source gives us the starting point. This is how we would build the next layer of research around it.

We would start by asking Labcorp how many of its anatomic pathology sites are live on AISight Dx today, not contracted.
Then we would check which AI applications are switched on beyond the viewer, since a cleared viewer is not a cleared algorithm.
We would ask the pathologists working in those labs whether digital sign out changed their reading time and their error rate.